Shao Yuan, Zhuang Jing, Xu Shu-xiang, Liu Ding-yi
Department of Urology, 2 Nanyang Medical RIA Center, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, P. R. China.
Ai Zheng. 2002 Sep;21(9):1005-7.
BACKGROUND & OBJECTIVE: There is no effective non-invasive monitoring method for transitional cell carcinoma of urinary tract(TCCU). It was recently reported that nuclear matrix protein 22(NMP22) could be used to diagnose TCCU. This study was designed to evaluate the significance of NMP22 in TCCU as a new urinary tumor marker and its influence factors.
The authors detected 87 patients with urinary system disease(including 29 cases with TCCU) with ELISA-NMP agent box. The patients with urinary infection were excluded.
The positive value was set at more than 10 u/ml. The sensitivity and specificity of NMP22 on TCCU were 86.2% and 94.3%, respectively (benign diseases of urinary system used as control), with significant advantages over voided-urine cytology (86.2% vs 42.3%, P < 0.001). The main factors that caused false-positive results were urinary infection, the other malignant tumors of urinary system, bowel interposition, and nephrolith.
Urinary NMP22 is a good tumor marker and could be used an alternation of voided-urine cytology for monitoring and diagnosis of TCCU.
目前尚无有效的非侵入性方法监测尿路移行细胞癌（TCCU）。最近有报道称核基质蛋白22（NMP22）可用于诊断TCCU。本研究旨在评估NMP22作为一种新型尿液肿瘤标志物在TCCU中的意义及其影响因素。
作者采用ELISA - NMP试剂盒检测了87例泌尿系统疾病患者（包括29例TCCU患者），排除了泌尿系统感染患者。
以10 u/ml以上为阳性值。NMP22对TCCU的敏感性和特异性分别为86.2%和94.3%（以泌尿系统良性疾病作为对照），明显优于尿脱落细胞学检查（86.2%对42.3%，P < 0.001）。导致假阳性结果的主要因素有泌尿系统感染、泌尿系统其他恶性肿瘤、肠道代膀胱术和肾结石。
尿NMP22是一种良好的肿瘤标志物，可作为尿脱落细胞学检查的替代方法用于TCCU的监测和诊断。
